Severe Morbidity and Mortality Risk From Malaria in the United States, 1985–2011
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Severe Morbidity and Mortality Risk From Malaria in the United States, 1985–2011
Filetype[PDF-669.38 KB]


Details:
  • Alternative Title:
    Open Forum Infect Dis
  • Personal Author:
  • Description:
    Background.  Recent reports of Plasmodium vivax associated with severe syndromes and mortality from malaria endemic areas questions the “benign” course of non-falciparum malarias. Methods.  We retrospectively analyzed data from patients reported to the US Centers for Disease Control and Prevention with a diagnosis of malaria parasite single-species infection between 1985 and 2011. Patients classified as having severe illness were further classified according to outcome (survival versus death) and clinical syndrome. Results.  Among all cases, .9% of Plasmodium falciparum cases resulted in death and 9.3% were classified as severe, whereas .09% of P. vivax cases resulted in death and 1.3% were classified as severe. The odds ratios for severe illness among 15 272 diagnoses of P. falciparum relative to patients diagnosed with P. vivax (n = 12 152), Plasmodium malariae (n = 1254), or Plasmodium ovale (n = 903) was 7.5, 5.7, and 5.0, respectively (P < .0001 for all); in contrast, the corresponding odds ratios for death among those severely ill was 1.6, 1.1, and .8 (P > .1 for all), respectively. Compared with P. vivax (n = 163), the odds of P. falciparum cases classified as severely ill (n = 1416) were 1.9 (P = .0006), .5 (P = .001), and 1.3 times (P = .1) as likely to present as cerebral, acute respiratory distress, and renal syndromes, respectively. Conclusions.  Although less common, patients presenting with non-falciparum even in the United States can develop severe illness, and severe illness in patients having malaria of any species threatens life.
  • Subject:
  • Document Type:
    Journal Article
  • Place as Subject:
    United States
  • Collection(s):
    CDC Public Access
  • Main Document Checksum:
  • File Type:
No Related Documents.

You May Also Like:

  1. Filetype[PDF - 110.51 KB]
    Personal Author:
    Plucinski, Mateusz M.; Huber, Curtis S.; Akinyi, Sheila; Dalton, Willard; Eschete, Mary; Grady, Katharine; Silva-Flannery, Luciana; Mathison, Blaine A.; Udhayakumar, Venkatachalam; Arguin, Paul M.; Barnwell, John W.;
    Published Date:
    Aug 05 2014
    Source:
    Open Forum Infect Dis. 2014; 1(2).
    Description:
    Background Atovaquone-proguanil (AP) is the most commonly used treatment for uncomplicated Plasmodium falciparum malaria in the United States. Apparent AP treatment failures were reported 7 months apart in 2 American travelers who stayed in the sam...
    File Type:
    Filetype[PDF - 110.51 KB]
  2. Filetype[PDF - 1.05 MB]
    Personal Author:
    Riveron, Jacob M; Watsenga, Francis; Irving, Helen; Irish, Seth R; Wondji, Charles S;
    Published Date:
    Jan 04 2018
    Source:
    J Infect Dis. 2017; 217(2):320-328.
    Description:
    Accounting for approximately 11% of all malaria cases, the Democratic Republic of the Congo (DRC) is central to malaria elimination efforts. To support vector control interventions in DRC, we characterized the dynamics and impact of insecticide resis...
    File Type:
    Filetype[PDF - 1.05 MB]
  3. Filetype[PDF - 332.64 KB]
    Personal Author:
    Lessa, Fernanda C.; Mu, Yi; Winston, Lisa G.; Dumyati, Ghinwa K.; Farley, Monica M.; Beldavs, Zintars G.; Kast, Kelly; Holzbauer, Stacy M.; Meek, James I.; Cohen, Jessica; McDonald, L. Clifford; Fridkin, Scott K.;
    Published Date:
    Jul 28 2014
    Source:
    Open Forum Infect Dis. 2014; 1(2).
    Description:
    Background Clostridium difficile infection (CDI) is no longer restricted to hospital settings, and population-based incidence measures are needed. Understanding the determinants of CDI incidence will allow for more meaningful comparisons of rates a...
    File Type:
    Filetype[PDF - 332.64 KB]
  4. Filetype[PDF - 449.60 KB]
    Personal Author:
    Patel, Pragna; Armon, Carl; Chmiel, Joan S.; Brooks, John T.; Buchacz, Kate; Wood, Kathy; Novak, Richard M.;
    Published Date:
    May 27 2014
    Source:
    Open Forum Infect Dis. 2014; 1(1).
    Description:
    Background. Little is known about survival and factors associated with mortality after cancer diagnosis among persons infected with human immunodeficiency virus (HIV).Methods. Using Poisson regression, we analyzed incidence rates of acquired immu...
    File Type:
    Filetype[PDF - 449.60 KB]
  5. Filetype[PDF - 904.62 KB]
    Personal Author:
    Wylie, Charles M.
    Published Date:
    Dec 1961
    Source:
    Public Health Rep. 76(12):1111-1116
    File Type:
    Filetype[PDF - 904.62 KB]